BolisG., ScartaneG., ZanaboniF., VillaA., PrestiM., MelpignanoM., FerrarisC., TateoS., GuarnerioP., GentileA., ParazziniF.: A Phase II Trial of Fixed-dose Carboplatin and Escalating Paclitaxel in Advanced Ovarian Cancer.Eur. J. Cancer.,33: 592–595, 1997.
2.
BookmanM.A., McGuirellW.P., KilpatrickD., KeenanE., HoganW.M., JohnsonS.W., O'DwyerP., RowinskyE., GallionH.H., OzolsR.: Carboplatin and Paclitaxel in Ovarian carcinoma: A Phase I Study of the Gynecologic Oncology Group”.J. Clin. Oncol.,14: 1895–1902, 1996.
3.
Du Bois A., Nitz U., Schroder W., Schiller S., Jackisch C., Luck H.J., Meier W., Mobus V. for the AGO Study Group:Cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line chemotherapy in ovarian cancer: Interim analysis of an AGO study Group trial.Proc. Am. Soc. Clin. Oncol.,16: 352a (Ab 1272), 1997.
4.
EisenhauerE.A., ten Bokkel HuininkW.W., SwenertonK.D., GianniL., MylesJ., van der BurgM.E.L., KerrI., VermorkenJ.B., BuserK., ColomboN., BaconM., SantabarbaraP., OnettoN., WinogradB., CanettaR.: European-canadian randomized Trial of Paclitaxel in Relapsed Ovarian Cancer: High-Dose Versus Low-Dose and Long Versus Short Infusion.J. Clin. Oncol.,12: 2654–2666, 1994.
5.
McGuireW.P., HoskinsW.J., BradyM.F., KuceraP.R., PartridgeE.E., LookK.Y., Clarke-PearsonD.L., DavidsonM.: Cyclophosphamide and Cisplatin compared with Paclitaxel and Cisplatin in Patients with Stage III and IV Ovarian Cancer.New Engl. J. Med.,334: 1–6, 1996.
6.
MeerpohlH.G., du BoisA., KuhnleH., LuckH.J., KreienbergR., MobusV., BauknechtT., KochliO., BochtlerH., DiergartenK., HeuserA.: Paclitaxel combined with carboplatin in the First-Line Treatment of Advanced Ovarian Cancer.Sem. Oncol.,22(suppl. 15): 7–12, 1995.
7.
NeijtJ.P., HansenM., HansenS.W., SorensenP.G., SessaC., WitteveenP.O., EngelholmS.A., StigaardL., RoerO., LundB.: Randomized Phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxelcisplatin and paclitaxel-carboplatin.Proc. Am. Soc. Clin. Oncol.16: 352a (Ab 1259), 1997.
8.
OmuraG.A., BradyM.F., DelmoreJ.E., LongH.J., LookK.Y., AveretteH.E., WaalerS., SpiegelG.: A randomized trial of paclitaxel (T) at 2 dose levels, and filgrastim (G;G-CSF) at 2 Doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): A Gynecologic Oncology Group, SWOG, NCCTG and ECOG study.Proc. Am. Soc. Clin. Oncol.,15: 280 (Ab 755), 1996.
9.
Ovarian Cancer Meta-analysis Project:Cyclophosphamide, Doxorubicin and Cisplatin Chemotherapy in ovarian carcinoma: a meta-analysis.J. Clin. Oncol.,9: 1668–1674, 1991.
10.
OzolsR.F.: Update of the NCCN Ovarian Cancer Practice Guidelines.Oncology,11(n°11A): 95–105, 1997.
11.
ParkerL.S., TongT., BoldenS., WingoP.A.: Cancer statistics, 1997.Ca. Cancer. J. Clin.,47: 5–27, 1997.
12.
PiccartM.J., BertelsenK., StuartG., JamesK., CassidyJ., KayeS., Hoctin BoesG., TimmersP., RoyJ.A., PecorelliS.: Is cisplatin-paclitaxel (P-T) the standard in first line treatment of advanced ovarian cancer (Ov Ca)? The EORT-GCCG, NOCOVA, NCI-C and Scottish intergroup experience.Proc. Am. Soc. Clin. Oncol.,16: 352a (Ab 1258), 1997.
13.
Society of Gynecologic Oncologists:Practice Guidelines: Ovarian Cance”.Oncology,12: 129–133, 1998.
14.
Stewart L.A. for Advanced Ovarian Cancer Trialist Group (AOCTG):Chemotherapy in Advanced Ovarian Cancer: an overview of randomized trials.Br. Med. J.,303: 884, 1991.
15.
Ten Bokkel HuininkW., VeenhofC., HuizingM., RodenhuisS., HelmerhorstT., DubbelmannR., DalesioO., BeijnenJ., WinogradB.: Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer: A Dose-Finding Study.Sem. Oncol.,24 n°1 (Suppl. 2): S2-31–S2-33, 1997.
16.
ThigpenJ.T., BlessingJ.A., BallH., HummelJ., BarrettR.J.: Phase II Trial of paclitaxel in Patients with Progressive Ovarian Carcinoma After Platinum-Based Chemotherapy: A Gynecologic Oncologic Group Study.J. Clin. Oncol.,12(Sept.): 1748–1753, 1994.
